# Kyowa Kirin, Inc. clinical trials: 36 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials with Kyowa Kirin, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kyowa Kirin, Inc.: 36 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/kyowa-kirin-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2025 | NCT07192471 | A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | Kyowa Kirin, Inc. | Phase 1 | Recruiting | T-cell NHL (PTCL or CTCL) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192471) |
| August 30, 2021 | NCT05027646 | Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches. | Kyowa Kirin, Inc. | Phase 1 | Completed | Healthy Volunteers | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05027646) |
| February 9, 2021 | NCT04745234 | Mogamulizumab Q4week Dosing in Participants With R/R CTCL | Kyowa Kirin, Inc. | Phase 2 | Unknown | Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04745234) |
| March 25, 2020 | NCT04321694 | Expanded Access for KHK2455 | Kyowa Kirin, Inc. | Not applicable | No longer available | Glioblastoma Multiforme | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04321694) |
| December 9, 2019 | NCT04190654 | Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite | Kyowa Kirin, Inc. | Phase 1 | Completed | Hepatic Impairment | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04190654) |
| November 1, 2019 | NCT04147910 | Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-KW-6356 | Kyowa Kirin, Inc. | Phase 1 | Completed | Healthy Male Subjects | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04147910) |
| July 10, 2019 | NCT04014374 | Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab | Kyowa Kirin, Inc. | Observational | Recruiting | Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04014374) |
| April 16, 2019 | NCT03915405 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Kyowa Kirin, Inc. | Phase 1 | Terminated | Urothelial Carcinoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03915405) |
| October 11, 2018 | NCT03703102 | Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis | Kyowa Kirin, Inc. | Phase 2 | Completed | Atopic Dermatitis | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03703102) |
| September 27, 2016 | NCT02915705 | Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH | Kyowa Kirin, Inc. | Phase 3 | Completed | X-Linked Hypophosphatemia | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02915705) |
| August 15, 2016 | NCT02867007 | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | Kyowa Kirin, Inc. | Phase 1 | Completed | Solid Tumor, Cancer, Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02867007) |
| April 25, 2016 | NCT02750618 | Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) | Kyowa Kirin, Inc. | Phase 2 | Completed | X-Linked Hypophosphatemia | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02750618) |
| March 10, 2016 | NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | Kyowa Kirin, Inc. | Phase 1/2 | Completed | Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma, HCC | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02705105) |
| January 6, 2016 | NCT02647866 | Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis | Kyowa Kirin, Inc. | Phase 2 | Completed | Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02647866) |
| September 1, 2015 | NCT02537431 | Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) | Kyowa Kirin, Inc. | Phase 3 | Completed | X-linked Hypophosphatemia | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02537431) |
| August 18, 2015 | NCT02526160 | Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) | Kyowa Kirin, Inc. | Phase 3 | Completed | X-linked Hypophosphatemia | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02526160) |
| February 9, 2015 | NCT02358473 | Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer | Kyowa Kirin, Inc. | Phase 1 | Completed | Non-Small Cell Lung Cancer | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02358473) |
| December 9, 2014 | NCT02312687 | Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) | Kyowa Kirin, Inc. | Phase 2 | Completed | X-Linked Hypophosphatemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02312687) |
| December 1, 2014 | NCT02304367 | Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) | Kyowa Kirin, Inc. | Phase 2 | Completed | Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS) | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02304367) |
| November 25, 2014 | NCT02301130 | Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | Kyowa Kirin, Inc. | Phase 1 | Completed | Advanced Solid Tumors | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02301130) |
| July 4, 2014 | NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | Kyowa Kirin, Inc. | Phase 1 | Terminated | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02181699) |
| June 13, 2014 | NCT02163577 | Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric... | Kyowa Kirin, Inc. | Phase 2 | Completed | X-linked Hypophosphatemia | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02163577) |
| November 20, 2012 | NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | Kyowa Kirin, Inc. | Phase 3 | Completed | Cutaneous T-Cell Lymphoma | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01728805) |
| June 25, 2012 | NCT01626664 | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | Kyowa Kirin, Inc. | Phase 2 | Completed | Adult T-cell Leukemia-Lymphoma | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01626664) |
| August 7, 2009 | NCT00955045 | A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy | Kyowa Kirin, Inc. | Phase 2/3 | Completed | Parkinson's Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00955045) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 2 |
| Phase 2 | 12 |
| Phase 2/3 | 1 |
| Phase 3 | 8 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Terminated | 5 |
| Recruiting | 2 |
| Unknown | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 8 |
| Familial Hypophosphatemic Rickets | 6 |
| Lymphoma, T-Cell, Cutaneous | 4 |
| Neoplasms | 3 |
| Carcinoma | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Myelodysplastic Syndromes | 2 |
| Lymphoma | 2 |
| Leukemia-Lymphoma, Adult T-Cell | 2 |
| Sezary Syndrome | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Leukemia | 1 |
| Nausea | 1 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Movement Disorders | 1 |
| Colitis, Ulcerative | 1 |
| Digestive System Diseases | 1 |
| Colitis | 1 |
| Gastrointestinal Diseases | 1 |
| Inflammatory Bowel Diseases | 1 |
| Intestinal Diseases | 1 |
| Colonic Diseases | 1 |
| Autoimmune Diseases | 1 |
| Abdominal Pain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Surgery practices in the United States](https://specstream.ai/data/businesses/surgery-practices/united-states)
- [Paper mills in the United States](https://specstream.ai/data/businesses/paper-mills/united-states)
- [HR services firms in the United States](https://specstream.ai/data/businesses/hr-services-firms/united-states)
- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
